系统性囊e) 酶的使用会诱导铁亡,并在质母细胞瘤中与temozolomide协同作用
Fahim Ahmad1,2, Blair P Rendina1,2, Chixiang Chen3,4,2
1Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.
iScience
|January 16, 2026
概括
这项研究表明,通过cyst(e) inase向囊蛋白代谢,可以克服质母细胞瘤的耐药性. 这种方法诱导质瘤干细胞中的铁亡,并与temozolomide协同,以提高抗瘤功效.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 质母细胞瘤 (GBM) 由于瘤异质性和适应性质母细胞 (GSCs) 的原因,对治疗具有高度耐药性.
- GSCs表现出对氨酸的代谢依赖,呈现出潜在的治疗脆弱性.
研究的目的:
- 调查系统性囊酶,一种降解囊蛋白的酶,对GSCs的疗效.
- 阐明囊酶诱导细胞死亡的机制及其克服GBM治疗耐药性的潜力.
主要方法:
- 使用患者衍生的GSC和正位异种移植模型.
- 给系统性囊e) 酶,并评估其对GSC增殖,存活率和铁亡标记物的影响.
- 研究了活性氧物种 (ROS),谷氨 (GSH),脂质过氧化,铁和长链乙烯基-CoA合成酶家族成员-4 (ACSL4) 的作用.
- 评估了cyst(e) inase与temozolomide (TMZ) 的协同效应.
主要成果:
- 囊酶通过诱导铁亡,强烈抑制了GSC的增殖,并延长了动物的存活时间.
- 铁性被通过ROS升高,GSH耗尽,脂质过氧化和线粒体变化证实,可通过N-乙半氨酸 (NAC) 和除胺 (DFX) 逆转.
- 在囊中,ACSL4对于因酶诱导的铁亡是必不可少的.
- 囊酶与TMZ协同作用,显著提高了抗瘤疗效和存活率,即使在耐TMZ模型中也是如此.
结论:
- 通过cyst(e) inase向囊蛋白代谢是对抗质母细胞瘤的一种有前途的策略.
- 囊酶有效地诱导GSC中的铁亡并克服治疗抵抗.
- 使用囊酶和TMZ的联合治疗提供了一种有效的方法来对抗GBM.
关键词:
微观环境是一个微观环境.更多相关视频
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.2K
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
1.8K
相关概念视频
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
